AU2023227010A1 - Diacylglycerol kinase (dgk) alpha inhibitors and uses thereof - Google Patents

Diacylglycerol kinase (dgk) alpha inhibitors and uses thereof Download PDF

Info

Publication number
AU2023227010A1
AU2023227010A1 AU2023227010A AU2023227010A AU2023227010A1 AU 2023227010 A1 AU2023227010 A1 AU 2023227010A1 AU 2023227010 A AU2023227010 A AU 2023227010A AU 2023227010 A AU2023227010 A AU 2023227010A AU 2023227010 A1 AU2023227010 A1 AU 2023227010A1
Authority
AU
Australia
Prior art keywords
compound
heterocycloalkyl
alkyl
cycloalkyl
heteroaryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2023227010A
Other languages
English (en)
Inventor
Xiao DING
Hongfu LU
Feng Ren
Huaxing YU
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
InSilico Medicine IP Ltd
Original Assignee
InSilico Medicine IP Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by InSilico Medicine IP Ltd filed Critical InSilico Medicine IP Ltd
Publication of AU2023227010A1 publication Critical patent/AU2023227010A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2023227010A 2022-03-01 2023-03-01 Diacylglycerol kinase (dgk) alpha inhibitors and uses thereof Pending AU2023227010A1 (en)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
CN2022078653 2022-03-01
CNPCT/CN2022/078653 2022-03-01
CN2022091497 2022-05-07
CNPCT/CN2022/091497 2022-05-07
CN2022127020 2022-10-24
CNPCT/CN2022/127020 2022-10-24
CNPCT/CN2023/071857 2023-01-12
CN2023071857 2023-01-12
PCT/CN2023/078948 WO2023165504A1 (en) 2022-03-01 2023-03-01 Diacylglycerol kinase (dgk) alpha inhibitors and uses thereof

Publications (1)

Publication Number Publication Date
AU2023227010A1 true AU2023227010A1 (en) 2024-09-12

Family

ID=87883011

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2023227010A Pending AU2023227010A1 (en) 2022-03-01 2023-03-01 Diacylglycerol kinase (dgk) alpha inhibitors and uses thereof

Country Status (12)

Country Link
US (2) US20240051958A1 (cg-RX-API-DMAC7.html)
EP (1) EP4486741A4 (cg-RX-API-DMAC7.html)
JP (1) JP2025508971A (cg-RX-API-DMAC7.html)
KR (1) KR20240156394A (cg-RX-API-DMAC7.html)
CN (1) CN118871438A (cg-RX-API-DMAC7.html)
AR (1) AR128669A1 (cg-RX-API-DMAC7.html)
AU (1) AU2023227010A1 (cg-RX-API-DMAC7.html)
CA (1) CA3244501A1 (cg-RX-API-DMAC7.html)
IL (1) IL315015A (cg-RX-API-DMAC7.html)
MX (1) MX2024010648A (cg-RX-API-DMAC7.html)
TW (1) TW202342477A (cg-RX-API-DMAC7.html)
WO (1) WO2023165504A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL315015A (en) 2022-03-01 2024-10-01 Insilico Medicine Ip Ltd Diacylglycerol kinase (DGK) alpha inhibitors and their uses
TW202436351A (zh) 2023-02-06 2024-09-16 德商拜耳廠股份有限公司 Ccr8抗體及dgk抑制劑之組合
CN122094689A (zh) * 2023-09-04 2026-05-26 英矽智能科技知识产权有限公司 二酰甘油激酶(DGK)α抑制剂与其他疗法的组合治疗

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100477070B1 (ko) 1994-03-25 2006-04-21 이소테크니카 인코포레이티드 중수소화작용에의한의약품의효능강화법
US6334997B1 (en) 1994-03-25 2002-01-01 Isotechnika, Inc. Method of using deuterated calcium channel blockers
TW200418829A (en) * 2003-02-14 2004-10-01 Avanir Pharmaceutics Inhibitors of macrophage migration inhibitory factor and methods for identifying the same
AU2004220176A1 (en) 2003-03-14 2004-09-23 Astrazeneca Ab Novel fused triazolones and the uses thereof
GB0420970D0 (en) 2004-09-21 2004-10-20 Smithkline Beecham Corp Novel triazoloquinoline compounds
AR064416A1 (es) * 2006-12-21 2009-04-01 Cancer Rec Tech Ltd Derivados de purina, piridina y pirimidina condensadas con heterociclos, moduladores de pka y/o pkb, composiciones farmaceuticas que los contienen, y usos para el tratamiento de enfermedades hiperproliferativas.
WO2011075747A1 (en) 2009-12-18 2011-06-23 Glaxosmithkline Llc Therapeutic compounds
US10376504B2 (en) * 2015-07-29 2019-08-13 Merck, Sharp & Dohme Corp. Substituted quinolinones as PDE9 inhibitors
CN111406050B (zh) * 2018-01-17 2023-02-03 厦门宝太生物科技股份有限公司 吲哚胺2,3-双加氧酶抑制剂及其用途
SG11202012973RA (en) 2018-06-27 2021-01-28 Bristol Myers Squibb Co Naphthyridinone compounds useful as t cell activators
CN112654621B (zh) 2018-06-27 2024-05-14 百时美施贵宝公司 可作为t细胞活化剂的经取代萘啶酮化合物
MA56444A (fr) 2019-07-04 2022-05-11 Lead Pharma Holding Bv MODULATEURS DU RÉCEPTEUR ALPHA DES OESTROGÈNES (ERRalpha)
AR119821A1 (es) 2019-08-28 2022-01-12 Bristol Myers Squibb Co Compuestos de piridopirimidinonilo sustituidos útiles como activadores de células t
HRP20240237T1 (hr) 2019-10-18 2024-05-10 Lead Pharma Holding B.V. Modulatori receptora alfa (err-alfa) povezanih s estrogenom
US12478621B2 (en) * 2019-11-28 2025-11-25 Deutsches Krebsforschungszentrum Substituted aminoquinolones as dgkalpha inhibitors for immune activation
WO2021105115A1 (en) 2019-11-28 2021-06-03 Bayer Aktiengesellschaft Substituted aminoquinolones as dgkalpha inhibitors for immune activation
EP4065584A1 (en) 2019-11-28 2022-10-05 Bayer Aktiengesellschaft Substituted aminoquinolones as dgkalpha inhibitors for immune activation
WO2021127554A1 (en) 2019-12-19 2021-06-24 Bristol-Myers Squibb Company Combinations of dgk inhibitors and checkpoint antagonists
CA3162979A1 (en) 2019-12-23 2021-07-01 Upender Velaparthi Substituted piperazine derivatives useful as t cell activators
MX2022007369A (es) 2019-12-23 2022-07-12 Bristol Myers Squibb Co Compuestos de quinolinonilo piperazina sustituidos utiles como activadores de celulas t.
IL294148A (en) 2019-12-23 2022-08-01 Bristol Myers Squibb Co Substituted quinazolinyl compounds are useful as t-cell activators
JP7677976B2 (ja) * 2019-12-23 2025-05-15 ブリストル-マイヤーズ スクイブ カンパニー T細胞アクティベーターとして有用な置換ヘテロアリール化合物
AR120823A1 (es) 2019-12-23 2022-03-23 Bristol Myers Squibb Co Compuestos bicíclicos sustituidos útiles como activadores de células t
CN115362003B (zh) 2019-12-24 2024-03-22 卡尔那生物科学株式会社 二酰基甘油激酶调节化合物
WO2021258010A1 (en) 2020-06-19 2021-12-23 Gossamer Bio Services, Inc. Oxime compounds useful as t cell activators
AU2021400725A1 (en) 2020-12-16 2023-08-03 Gossamer Bio Services, Inc. Compounds useful as t cell activators
CN117355531A (zh) 2021-06-23 2024-01-05 吉利德科学公司 二酰基甘油激酶调节化合物
JP7651018B2 (ja) 2021-06-23 2025-03-25 ギリアード サイエンシーズ, インコーポレイテッド ジアシルグリセロールキナーゼ調節化合物
EP4359413A1 (en) 2021-06-23 2024-05-01 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
MX2023014762A (es) 2021-06-23 2024-01-15 Gilead Sciences Inc Compuestos moduladores de diacilglicerol quinasa.
CA3228862A1 (en) 2021-08-03 2023-02-09 Beigene, Ltd. Pyrazolopyridinone compounds
WO2023165528A1 (en) 2022-03-01 2023-09-07 Insilico Medicine Ip Limited Diacylglycerol kinase (dgk) alpha inhibitors and uses thereof
EP4486745A4 (en) 2022-03-01 2026-03-11 Insilico Medicine Ip Ltd Diacylglycerol Kinase (DGK) Alpha Inhibitors and Their Uses
WO2023165525A1 (en) 2022-03-01 2023-09-07 Insilico Medicine Ip Limited Diacylglycerol kinase (dgk) alpha inhibitors and uses thereof
IL315015A (en) 2022-03-01 2024-10-01 Insilico Medicine Ip Ltd Diacylglycerol kinase (DGK) alpha inhibitors and their uses
JP2025510945A (ja) 2022-03-31 2025-04-15 インベンティスバイオ カンパニー リミテッド キナーゼ阻害剤、その製造方法および用途
WO2023184327A1 (en) 2022-03-31 2023-10-05 InventisBio Co., Ltd. Kinase inhibitors, preparation methods and uses thereof

Also Published As

Publication number Publication date
EP4486741A1 (en) 2025-01-08
IL315015A (en) 2024-10-01
WO2023165504A1 (en) 2023-09-07
KR20240156394A (ko) 2024-10-29
EP4486741A4 (en) 2026-04-08
US12077538B2 (en) 2024-09-03
CA3244501A1 (en) 2023-09-07
US20240051958A1 (en) 2024-02-15
TW202342477A (zh) 2023-11-01
JP2025508971A (ja) 2025-04-10
US20240116935A1 (en) 2024-04-11
CN118871438A (zh) 2024-10-29
MX2024010648A (es) 2024-11-08
AR128669A1 (es) 2024-06-05

Similar Documents

Publication Publication Date Title
WO2024255795A1 (en) Kras inhibitors and uses thereof
US12077538B2 (en) Diacylglycerol kinase (DGK) alpha inhibitors and uses thereof
WO2023165525A1 (en) Diacylglycerol kinase (dgk) alpha inhibitors and uses thereof
KR20250145706A (ko) 아제티딘 및 피롤리딘 parp1 저해제, 및 이의 용도
WO2023066283A1 (en) Methionine adenosyltransferase 2a (mat2a) inhibitors and uses thereof
WO2023165528A1 (en) Diacylglycerol kinase (dgk) alpha inhibitors and uses thereof
EP4486745A1 (en) Diacylglycerol kinase (dgk) alpha inhibitors and uses thereof
WO2023155892A1 (en) Membrane-associated tyrosine-and threonine-specific cdc2-inhibitory kinase (pkmyt1) inhibitors and uses thereof
WO2023174397A1 (en) Pyrazole membrane-associated tyrosine-and threonine-specific cdc2-inhibitory kinase (pkmyt1) inhibitors and uses thereof
WO2023241627A1 (en) Cdk8/19 dual inhibitors and methods of use thereof
WO2024131939A1 (en) Cbl-b inhibitors and methods of uses thereof
WO2024141015A1 (en) Protein tyrosine phosphatase inhibitors and uses thereof
EP4642777A1 (en) Inhibitors of kif18a and uses thereof
WO2025067468A1 (en) Cbl-b inhibitors and methods of uses thereof
WO2025051110A1 (en) Combinations treatments of diacylglycerol kinase (dgk) alpha inhibitors and other therapies
WO2026103103A1 (en) Novel compounds as myt1 inhibitors and uses thereof
EA052540B1 (ru) Ингибиторы альфа-диацилглицеринкиназы (дгк) и способы их применения
WO2025060975A1 (en) Novel compounds as pkmyt1 inhibitors and use thereof
WO2024193542A1 (en) Inhibitors of fgfr2 and fgfr3 and uses thereof
WO2023193759A1 (en) Hpk1 antagonists and uses thereof
WO2024183726A1 (en) Cdk8/19 dual inhibitors and methods of use thereof
HK40117800A (en) Diacylglycerol kinase (dgk) alpha inhibitors and uses thereof
WO2026067453A1 (en) Novel compounds as nlrp3 inflammasome inhibitors and uses thereof
WO2024061300A1 (en) Inhibitors of trex1 and uses thereof
WO2025261355A1 (en) Werner syndrome recq helicase (wrn) inhibitors and methods of uses thereof